Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.63 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993082 | 0.90 | MET (0.62) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL12595668 | 0.89 | MET (0.56) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL1983683 | 0.89 | MET (0.61) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL1984128 | 0.88 | MET (0.61) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL12595674 | 0.86 | MET (0.51) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL1583435 | 0.85 | MET (0.62) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL1583727 | 0.82 | MET (0.71) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL12595260 | 0.80 | MET (0.51) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL1583574 | 0.80 | MET (0.56) | METDRD5HTR2CHTR6RPS6KA3 | |
| SCHEMBL12808129 | 0.79 | MET (0.55) | METDRD5HTR2CHTR6RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499124-B1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-9018234-B2 | Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20130005773-A1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-03 | — | — | US | disclosed |
| WO-2011069761-A1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005773-A1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | MET, RET, ABL1 | MET 1/4885DRD5 1789/4885HTR2C 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.